Jinli Wei, * Yulin Luo, * Deyuan Fu
Thyroid Division and Meaning Medicine, People's Hospital Northern Jiangsu, Yangzhou 225001, Jiangsu, Chinese Public Republic
* These authors added this work fairly
Reason: To better clarify the effectiveness of neoadjuvant bevacizumab plus chemotherapy (BEV + CT) vs. chemotherapy (CT) only when HER2-negatic breast cancer is not dissatisfied.
Methods: PubMed, Embase, Web of Science and Stòr Cochrane have been searched for Stòrlann for relevant articles published from 1 January 2000 to 31 July 2018. Draft software 5.3 of the Review Manager was used to achieve this met-analysis .
Results: Six controlled tests decided outside the electoral criteria, which issued 4,354 patients with early results and 3,777 patients with late results. Total pathology response rates (pCR) and 5-year voluntary survival rates (DFS) were higher for their non-advanced BEV + CT (OR = 1.37 [1.19, 1.58]; P<0.001 and HR = 0.84 [0.72, 0.98]; P= 0.020, respectively), but the total 5-year (OS) level showed that there was no significant difference (HR = 0.79 [0.55, 1.11]; P= 0.180). Sub-group analysis showed that pCR levels were significantly higher in both breastfeeding patients (receptor hormone receptor (HR) – advanced (OR = 1.30 [1.01, 1.66]; P= 0.040) and those with AD negative breast cancer (OR = 1.52 [1.25, 1.83]; P<0.001) in a BEV + CT group.
Decision: Compared to CT alone, BEV + CT non-advanced significantly improved the 5-year DFS level of HER2 negative chronic cancer patients, but did not show a benefit for a 5-year OS level.
Keywords: bevacizumab, non-advanced chemotherapy, chronic cancer, HER2-negative test, controlled by banned
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and a & # 39; including Creative Commons Attribution – Non Commercial (unported, v3.0).
By entering the work that you are doing; accept these terms. Non-commercial use of the work is licensed without any permission from Dove Medical Press Limited, as long as the work is correctly identified. For permission for commercial use of this work, see paragraphs 4.2 and 5 of our Terms.[ad_2]